search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
22 LONGEVITY Keratinocyte-melanocyte models have


shown senescent melanocytes can cause a DNA damage response in surrounding keratinocytes, reduce their proliferation, and result in a thinner epidermis.8


and fibroblasts, showed increasing levels of senescent fibroblasts led to skin thinning and barrier disruption.9


The new paradigm: uniting traditional with longevity While the new evidence highlighting the hallmarks of ageing opens new modes of treatment, what about all the existing modes of treatment? Retinoids have decades of research elucidating their mechanisms of action, strong clinical benefits, and are among the most consumer accepted ingredients available. Peptides as a category have countless mechanisms of action across growth factor mimics to anti-inflammatory solutions to matrikines, all with clinical validation. The strength of evidence supporting these treatments is currently well above new longevity approaches, mainly because they have been studied longer and more thoroughly. They may not directly impact the hallmarks of ageing to the extent new longevity approaches do, but this leads us to our next key question: if the end clinical result is the same, does it matter how we get there? This is especially relevant considering the


limited economic space and routine share for consumers. Consumers are deeply habituated to traditional actives that have likely worked for years. Especially with the rise of agentic commerce


and AI-assisted queries, the competition between actives and the importance of their track record will only increase with time. Do consumers spend the extra money to also incorporate longevity actives? Do they change their routines to replace traditional actives with these new approaches? While there are many potential answers


to these questions, I believe the most potent response is best exemplified by invoking our previous analogy of the Hindu deity Shiva. The prior balance of anti-ageing actives is being incinerated and from their ashes a new harmony is being built. The new age, targeting well ageing and preventative care, involves identifying modes of synergy between both approaches.


A new harmony: Bakuchiol NAD+ BCR


Bakuchiol NAD+ BCR – hereafter, the bakuchiol NAD+ ester - is a new ingredient that was designed exactly with this in mind. It is the fusion of a traditional anti-ageing active (bakuchiol) with an NAD+ precursor to target longevity (nicotinic acid) into one ester with powerful synergy (bakuchiyl nicotinate).


Another model, this time keratinocytes


Figure 1: The hallmarks of ageing paper often cited as a review of ageing research condensed into one mental model3


Ester fusion technology allows consumers


to receive the benefits of both worlds without the additional economic or routine inflating burden. The identification of one key molecule also provides greater track record for AI-assisted queries and agentic commerce over extracts that may obfuscate results since extracts can vary significantly in efficacy. Nicotinic acid has been shown to convert


to NAD+ through the Preiss Handler pathway in multiple cell types, including keratinocytes.10,11 NAD+ plays a key role in energy production, DNA repair, epigenetic regulation, and inflammation. NAD+ accepts electrons from various processes


breaking down nutrients and transfers those electrons required for optimal energy production. Sirtuins and PARPs utilize NAD+ for their activities and release niacinamide as a byproduct. For all these reasons and more, NAD+ is a central target in longevity. NAD+ levels decline with age for several


reasons, three main ones to highlight: chronic inflammation, overwhelmed DNA repair systems, and reduced NAD+ production efficiency. Chronic


low-grade inflammation is a known quality of ageing skin, aptly termed ‘inflammaging’.12 Inflammatory signalling compounds such


as CD38 break down NAD+ for their activities, this means that over time more NAD+ is utilized for inflammation and less is available to keep cells ‘young/effective’. Concurrently, the stress defence systems of cells (including DNA repair) get overwhelmed with time. This is especially the case with photoageing,


highlighting the importance of sunscreens. Sirtuins and PARPs are important examples; both compounds are pivotal for DNA repair and regulating the epigenome/proteome to maintain youthful skin. When these systems are overwhelmed by


their damage mitigation faculties, it further shrinks the amount of resources placed on maintaining the orderly biological information necessary for youthfulness. Finally, the efficiency of NAD+ production


shrinks with time. One of the main ways NAD+ is produced in cells is through recycling of Niacinamide, NAMPT is the limiting factor enzyme


Figure 2: A theoretical framework for one route how ageing might occur based on known hallmarks PERSONAL CARE MAGAZINE May 2026 www.personalcaremagazine.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100